FDA approves Lutathera® for pediatric patients with gastroenteropancreatic neuroendocrine tumors May 1, 2024
OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for R/R BRAF-altered Pediatric Low-Grade Glioma (pLGG) May 1, 2024
XTANDI (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting May 1, 2024
FDA Approves Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer April 23, 2024
U.S. FDA Approves Abecma for Triple-Class Exposed R/R Multiple Myeloma After Two Prior Lines of Therapy April 8, 2024
Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumours April 8, 2024
CARVYKTI® Approved by the U.S. FDA for Patients with R/R Multiple Myeloma Who Have Received at Least One Prior Line of Therapy April 8, 2024
European Commission Approves KEYTRUDA + Chemo as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable NSCLC at High Risk of Recurrence in Adults April 2, 2024
Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer April 2, 2024
FDA grants accelerated approval to ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL March 26, 2024
FDA Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for FRα-positive, platinum-resistant ovarian cancer (PROC) March 26, 2024
NMPA grants Approval to Tunlametinib (HL-085) for Patients with NRAS Mutated Advanced Melanoma and Previously Treated with PD-1/PD-L1 March 26, 2024
Abecma (idecabtagene vicleucel) Approved in the European Union in Earlier Lines for Triple-Class Exposed R/R Multiple Myeloma March 26, 2024
FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy March 19, 2024
U.S. FDA Approves Opdivo + Cisplatin + Gemcitabine for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma March 12, 2024
RYBREVANT® (amivantamab-vmjw) + Chemo gets FDA approval for First-line Treatment of Patients With NSCLC with EGFR Exon 20 Insertion Mutations March 12, 2024
TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with R/R multiple myeloma February 26, 2024
Tagrisso with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer February 26, 2024
